Recurrent Adult Immunoblastic Large Cell Lymphoma Completed Phase 3 Trials for Filgrastim (DB00099)

IndicationStatusPhase
DBCOND0028500 (Recurrent Adult Immunoblastic Large Cell Lymphoma)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00002649Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's LymphomaTreatment